Celldex Therapeutics, Inc.
corporate_fare Company Profile
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for CLDX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
- Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
- Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
- Celldex Accelerates Barzolvolimab Phase 3 Enrollment, Reports Q4/FY25 Results & 2026 Pipeline Catalysts
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$1.54M
Net Income
-$258.76M
Diluted EPS
-$3.90
Op. Cash Flow
-$210.94M
Free Cash Flow
-$213.66M
Gross Profit
$1.34M
Operating Income
-$287.37M
Cash & Equivalents
$28.87M
Debt / Equity
0.00×
Net Margin
-167.48×
Shares Outstanding
66.55M sh
Source: 10-K · filed 2026-02-25 · accession 0001104659-26-019652
show_chartPrice Chart
Loading chart...
feed CLDX - Filings & News (Page 2)
CLDX
Mar 01, 2026, 9:45 AM EST
Price at Filing:
$28.67
Real-time Price:
$27.40
Change:
-$1.27 (-4%)
Market Cap:
$2.154B
CLDX
Feb 27, 2026, 2:45 PM EST
Price at Filing:
$29.55
Real-time Price:
$27.40
Change:
-$2.15 (-7%)
Market Cap:
$2.154B
CLDX
Feb 25, 2026, 4:06 PM EST
Price at Filing:
$30.82
Real-time Price:
$27.40
Change:
-$3.42 (-11%)
Market Cap:
$2.154B
CLDX
Feb 25, 2026, 4:01 PM EST
Price at Filing:
$29.50
Real-time Price:
$27.40
Change:
-$2.10 (-7%)
Market Cap:
$2.154B